Lyell Immunopharma, Inc.·4

Mar 18, 4:07 PM ET

Homans Elizabeth 4

4 · Lyell Immunopharma, Inc. · Filed Mar 18, 2022

Insider Transaction Report

Form 4
Period: 2022-03-16
Homans Elizabeth
DirectorChief Executive Officer
Transactions
  • Award

    Option (right to buy)

    2022-03-16+1,479,5001,479,500 total
    Exercise: $5.98Exp: 2032-03-15Common Stock (1,479,500 underlying)
Footnotes (1)
  • [F1]12.5% of the option shares shall vest on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION